Talazoparib and its Impurities

Talazoparib, sold under the brand name Talzenna, is an orally available poly ADP ribose polymerase inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Reference standards of Talazoparib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.